Zytiga is Most Used First-Line Treatment for Stage IV Prostate Cancer
April 25, 2013 -- Market data released this week shows the new drug’s share of the first-line prostate cancer market has steadily increased to 30 percent since its launch in 2011. The development of this novel new treatment was supported by PCF-funded research.
PCF funded both early science for the development of Zytiga and clinical trials that helped move this promising new drug to patients. Prior to the increased use of Zytiga to treat patients with advanced Stage IV disease, chemotherapy was used to treat three-fourths of first-line patients. Within a month of the FDA’s expanded usage ruling, use of Zytiga rose to 43 percent in first-line therapy for advanced prostate cancer.